The Impact of Immunotherapy Use in Stage IIIA (T1-2N2) NSCLC: A Nationwide Analysis

Introduction: Multiple clinical trials have revealed the benefit of immunotherapy (IO) for NSCLC, including unresectable stage III disease. Our aim was to investigate the impact of IO use on treatment and outcomes of potentially resectable stage IIIA NSCLC in a broader nationwide patient cohort. Met...

Full description

Bibliographic Details
Main Authors: Lye-Yeng Wong, MD, Douglas Z. Liou, MD, Mohana Roy, MD, Irmina A. Elliott, MD, Leah M. Backhus, MD, Natalie S. Lui, MD, Joseph B. Shrager, MD, Mark F. Berry, MD
Format: Article
Language:English
Published: Elsevier 2024-03-01
Series:JTO Clinical and Research Reports
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364324000249